Treating Low-Risk HER2-Positive Breast Cancer
Published Online: Thursday, January 23, 2014
For High-Definition, ClickThe regimens utilized to treat HER2-positive breast cancer continue to evolve as new therapies gain approval. By and large, HER2 status is being determined at a much earlier stage. Moreover, the increased efficacy of HER2-targeted therapies represents the potential to alter accompanying chemotherapeutics without significantly changing outcomes.
In the phase II TRYPHAENA study, 225 patients with HER2-positive early-stage breast cancer were treated with TCH (Taxotere, Carboplatin, Herceptin) plus pertuzumab or an anthracycline-based chemotherapy with or without pertuzumab and trastuzumab followed by pertuzumab, trastuzumab, and docetaxel. In general, the pathologic complete response (pCR) rates with these treatments were similar, Joyce A. O’Shaughnessy, MD, states. In fact, the pCR with TCH plus pertuzumab was 63.6% compared with the anthracycline-based regimens, which had a pCR rate around 55%. As a result, O’Shaughnessy prefers to administer anthracycline free regimens.
The primary endpoint of the TRYPHAENA study was cardiac safety, points out Hope S. Rugo, MD. Along with the secondary efficacy findings, the TCH plus pertuzumab regimen also demonstrated a marked reduction in toxicity, making it an appealing option, Rugo believes.
It is reasonable to present both options to patients, believes Mark D. Pegram, MD. Moreover, studies have shown that carboplatin can be omitted from the TCH regimen without significantly altering outcomes, even without the addition of an anthracycline, Pegram says.
For patients who do not tolerate docetaxel/carboplatin, Rugo recommends a switch to weekly paclitaxel with low-dose carboplatin. In a single-arm phase II study, weekly paclitaxel with trastuzumab was explored as a treatment for patients with low-risk HER2-positive breast cancer. This study demonstrated impressive findings, Rugo states. A randomized follow-up trial will compare paclitaxel plus trastuzumab to T-DM1.
View More From This Discussion
Kimberly L. Blackwell, MDProfessor of Medicine
Assistant Professor in Radiation Oncology
Duke Cancer Institute
Durham, North Carolina
Joyce A. O’Shaughnessy, MDCo-Director, Breast Cancer Research
Baylor Charles A. Sammons Cancer Center
Texas Oncology, PA/US Oncology,
Mark D. Pegram, MDProfessor of Medicine (Oncology)
Stanford University Medical Center;
Susy Yuan-Huey Hung Professor;
Associate Director of Clinical Research and Director, Breast Cancer Program, Stanford Cancer Institute, Stanford, California
Hope S. Rugo, MDProfessor of Medicine and Director of the Breast Oncology, Clinical Trials, and Education Program, University of California San Francisco Comprehensive Cancer Center, San Francisco, California
Denise A. Yardley, MDSenior Investigator, Breast Cancer Research
Sarah Cannon Research Institute, Tennessee Oncology, Nashville, Tennessee
Online CME Activities
Most Popular Right Now
The content contained in this video is for general information purposes only. The viewer is encouraged to confirm the information presented with other sources. OncLiveTV Peer Exchange makes no representations or warranties of any kind about the completeness, accuracy, timeliness, reliability, or suitability of any of the information, including content or advertisements, contained in this video and expressly disclaims liability for any errors and omissions that may be presented in this video. OncLiveTV Peer Exchange reserves the right to alter or correct any error or omission in the information it provides in this video, without any obligations. OncLiveTV Peer Exchange further disclaims any and all liability for any direct, indirect, consequential, special, exemplary, or other damages arising from the use or misuse of any material or information presented in this video. The views expressed in this video are those of the panelists and do not necessarily reflect the opinion or policy of OncLiveTV Peer Exchange.